This site is intended for healthcare professionals

Představení titulu

Novinky z letošního nejvýznamnějšího evropského setkání hematologů 2017

Originální název:
Novinky z letošního nejvýznamnějšího evropského setkání hematologů

Datum vydání: 10/2017


Formát: 210×270 mm

Počet stran: 92

Vazba: V1 ?Listy jsou spojeny sponkou ve hřbetu

Jazyk: čeština

Náhled PDF


Anotace

Publikace přináší souhrnnou informaci o nejdůležitějších sděleních týkajících se anémie, imunitní trombocytopenie, akutní myeloidní leukemie, myelomu, myelodysplastického syndromu, chronické myeloidní leukemie a lymfomu. Prezentace zazněly na kongresu Evropské hematologické asociace, který proběhl ve dnech 22.–25. června 2019 v Madridu.



Obsah

Novinky z 22. kongresu evropské hematologické asociace týkající se anémií
Jarolav Čermák
 
TRANSPLANTATION IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA OVER THE AGE OF 40: MORTALITY HAS NOT BEEN REDUCED IN 2010-2015
Sabrina Giammarco, Sica Simona, Carlo Dufour, et al.
 
EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
Britta Höchsmann, Flore Sicre de Fontbrune, Jong Wook Lee, et al.
 
INTRAVENOUS IRON VERSUS ORAL IRON VERSUS NO IRON WITH OR WITHOUT ERYTHROPOIESISSTIMULATING AGENTS (ESA) FOR CANCER PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Aaron Weigl, Nicola Köhler, Ina Monsef, et al.
 
Zpráva z kongresu Evropské hematologické asociace, zaměřená na imunitní trombocytopenii
Tomáš Kozák
 
REAL WORLD EVIDENCE ON DRUG UTILIZATION PATTERNS OF ELTROMBOPAG IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA: REVIEU (REVOLADE™ [ELTROMBOPAG] IN SELECTED COUNTRIES IN THE EUROPEAN UNION) STUDY
Emilio Ojeda Gutiérrez, Abdulgabar Salama, Jean-François Viallard, et al.
 
TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
J Bussel, J Mayer, L Cervinek, K Chojnowski, et al.
 
SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
James Bussel, Michael Tarantino, Victor Blanchette, et al.
 
AKUTNÍ MYELOIDNÍ LEUKEMIE – NOVINKY Z KONFERENCE EVROPSKÉ HEMATOLOGICKÉ SPOLEČNOSTI
Tomáš Stopka
 
VALIDATION OF EUROPEAN LEUKEMIA NET (ELN) GUIDELINES FOR CYTOGENETICALLY NORMAL AML IN ASSOCIATION WITH NPM1 AND FLT3-ITD MUTATIONS: FURTHER STRATIFICATION FOCUSING ON WT1 EXPRESSION
Jae-Ho Yoon, Hee-Je Kim, Young-Woo Jeon, et al.
 
RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
Hervé Dombret, John F. Seymour, Aleksandra Butrym, et al.
 
ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO REQUIRE TWO COURSES OF INDUCTION THERAPY TO ACHIEVE COMPLETE REMISSION (CR) SHOULD UNDERGO ALLOGENEIC TRANSPLANT (ALLO-SCT) DURING THE FIRST CR
Hiroaki Shimizu, Hiroshi Handa, Nahoko Hatsumi, et al.
 
QUIZARTINIB (AC220) IN PATIENTS WITH FLT3-ITD(+) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A RANDOMIZED PHASE 2 STUDY
Nigel Russell, Martin S. Tallman, Stuart Goldberg
 
MNOHOPOČETNÝ MYELÓM
Zdenka Štefániková
 
EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Jesus San-Miguel, Katja Weisel, Gordon Cook, et al.
 
MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE EMN02/HO95 PHASE 3 TRIAL
Stefania Oliva, Davine Hofste op Bruinink, Lucie Říhová, et al.
 
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY
Charlotte Pawlyn, Faith Davies, David Cairns, et al.
 
POMALIDOMID IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH MYELOMA GROUP
Ludek Pour, Lucie Brozova, Ivan Spicka, et al.
 
Aktuality z EHA 2017 zaměřené na chronickou myeloidní leukemii
Hana Klamová
 
IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY
Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
 
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
Timothy Hughes, Carla Boquimpani, Naoto Takahashi, et al.
 
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV
Ruediger Hehlmann, Michael Lauseker, Susanne Saussele, et al.
 
5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et al. Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et al.
 
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
Timothy Hughes, Carla Boquimpani, Naoto Takahashi, Noam Benyamini, Nelma Cristina Clementino, Vasily Shuvaev, Sikander Ailawadhi, Jeffrey Lipton, Anna Turkina, Raquel de Paz, Beatriz Moiragh, Franck Nicolini, Jolanta Dengler, Tomasz Sacha, Dong-Wook Kim, Rafik Fellague-Chebra, Sandip Acharya, Nancy Krunic, Yu Jin, François-Xavier Mahon
 
DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE
David Ross, Tamas Masszi, María Teresa Gómez Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentin Garcia Gutier­rez, Norbert Gattermann, Philipp le Coutre, Bruno Martino, Susanne Saussele, Francis Giles, Jerald Radich, Giuseppe Saglio, Prashanth Gopalakrishna, Weiping Deng, Nancy Krunic, Veronique Bedoucha, Andreas Hochhaus
 
SATELLITE SYMPOSIUM REPORT
Libor Červinek
 
Kongres Evropské hematologické společnosti
Libor Červinek
 
UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
Guillermo Montalban-Bravo, Prithviraj Bose, Yesid Alvarado, et al.
 
DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE
M Teresa Cedena, Fátima Mirás, Rosa M Ayala, et al.
 
A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
Aaron T. Gerds, Bart L. Scott, Peter Greenberg, et al.
 
PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE SHOW SIMILAR SURVIVAL PATTERNS AS LOW RISK MDS PATIENTS
Jakob Werner Hansen, Maj Westman, Andreas Due Orskov, et al.
 
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL) IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
Wolfgang Hiddemann, Anna Maria Barbui, Miguel Angel Canales Albendea, Paul K Cannell, Graham P Collins, Jan Dürig, Roswitha Forstpointner, Mi­chael Herold, Mark Hertzberg, Magdalena Klanova, John A Radford, Kensei Tobinai, Alis Burciu, Günter R Fingerle-Rowson, Tina Nielsen, Marcel Wolbers, Robert E Marcus
 

Tiráž

Vydavatelství: We Make Media, s. r. o. | Jednatelka: MUDr. Ivana Kaderková
Adresa: Italská 24, 120 00 Praha 2, Česká republika | Tel.: +420 778 476 475 | E-mail: info@wemakemedia.cz | www.wemakemedia.cz
Odpovědná redaktorka: PhDr. Jana Vytlačilová | Jazyková redaktorka: PhDr. Hana Kaiserová
Zlom a grafická úprava: We Make Media, s. r. o. | ISBN: 978–80–87339–33–6 | Vyšlo: říjen 2017

Jakékoliv kopírování a šíření celého obsahu nebo jeho části, a to ať v tištěné, nebo v elektronické formě je bez souhlasu vydavatelství zakázáno.
Vychází 1 x ročně | 1. ročník | V publikaci byly s povolením Evropské hematologické asociace použité texty a fotografie ze zdroje:
https://www.ehaweb.org/. All rights reserved. © 2017 European Hematology Association.



Komerce

Partneři projektu